TY  - CONF

T1  - A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.

JO  - JOURNAL OF CLINICAL ONCOLOGY

PY  - 2022/01/01

AU  - Jones RJ

AU  - Hussain SA

AU  - Birtle AJ

AU  - Song YP

AU  - Enting D

AU  - Faust G

AU  - Hilman S

AU  - Jagdev S

AU  - McGovern UB

AU  - Parikh O

AU  - Lewis A et al

ED  - 

VL  - 40

IS  - 17

Y2  - 2024/12/22

ER  -